Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification
- “Miracle Weight-Loss Drug” Sweeps Across America
- The United States Avian Influenza Outbreak Worse Than Expected?
- Global First: Bovine Avian Influenza Transmission to Humans Detected
- Potassium-Enriched Salt Substitutes: Reducing Blood Pressure Risk?
- Tritium Detection in Fukushima’s Seawater: Below Safety Standards
- What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?
Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification
According to a report by Japan’s Yomiuri Shimbun on April 27th, the manufacturer of the well-known medicine Seirogan, Japan Kyotou Co., Ltd., has been exposed for falsifying data for 30 consecutive years. The local government has ordered the company to suspend production and sales of this medicine.
Records show that Seirogan has a history of over 100 years and has been promoted for its “treatment of gastrointestinal discomfort,” selling well in Japan and overseas.
The report cited a notification from the Toyama Prefectural Government, where Kyotou Co., Ltd. is located, stating that during a recent surprise inspection, it was found that the effective ingredients in the medicine were significantly different from the advertised efficacy. What’s worse, in order to conceal the truth, Kyotou Co., Ltd. has been tampering with experimental data for the past 30 years, allowing Seirogan to pass inspections and be marketed.
Regarding the inspection results, Kyotou Co., Ltd. admitted and apologized to consumers. As of now, the company has voluntarily recalled 5.16 million units of Seirogan that have been distributed to the market.
Currently, based on the Japanese Pharmaceutical and Medical Devices Act, the Toyama Prefectural Government has ordered Kyotou Co., Ltd. to suspend sales on the 22nd and production on the 23rd starting from April 30th.
Recently, there have been continuous controversies involving Japanese pharmaceutical companies. According to previous reports, a health product containing red yeast rice produced by the well-known Japanese pharmaceutical company Kobayashi Pharmaceutical has caused a major uproar, resulting in health damage to consumers. As of April 24th, five people have died and 257 people have been hospitalized after taking the company’s implicated health product.
Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification
References:
正露丸を不適切製造 キョクトウに業務停止 虚偽の試験記録で出荷
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
